Fixed dose combination (antiretroviral)

From Wikipedia, the free encyclopedia

Fixed dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed dose combinations are shown in the table below.

Brand Name Drug Names (INN) Date of FDA Approval Company
Combivir zidovudine + lamivudine September 26, 1997 GlaxoSmithKline
Trizivir abacavir + zidovudine + lamivudine November 15, 2000 GlaxoSmithKline
Kaletra lopinavir + ritonavir September 15, 2000 Abbott Laboratories
Epzicom (in USA)
Kivexa (in Europe)		 abacavir + lamivudine August 2, 2004 GlaxoSmithKline
Truvada emtricitabine + tenofovir August 2, 2004 Gilead Sciences
Atripla efavirenz + emtricitabine + tenofovir July 12, 2006 Gilead Sciences and
Bristol-Myers Squibb

[edit] See also

v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Atazanavir° • Brecanavir§ • Fosamprenavir° • Lopinavir° • Darunavir • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir‡ • Indinavir‡
Entry/fusion inhibitors
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. §Development terminated.